We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+41.95%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$64.1M
AUM Growth
+$29.1M
Cap. Flow
+$15.2M
Cap. Flow %
23.73%
Top 10 Hldgs %
99.57%
Holding
12
New
2
Increased
2
Reduced
2
Closed
1

Top Buys

1
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$275K
2
GARS
Garrison Capital Inc.
GARS
+$23.8K
3
ICMB icon
Investcorp Credit Management BDC
ICMB
+$19.6K

Top Sells

1
CDTX
Cidara Therapeutics
CDTX
+$162K
2
ACRS icon
Aclaris Therapeutics
ACRS
+$85K
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$306

Sector Composition

1 Healthcare 61.55%
2 Financials 3.22%
3 Consumer Discretionary 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SBBP
1
DELISTED
Strongbridge Biopharma plc.
SBBP
$38.6M 60.18%
5,394,994
– –
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$15.3M 23.83%
+63,183
New +$15.1M
AGRX
3
DELISTED
Agile Therapeutics
AGRX
$6.09M 9.5%
812
– –
BRK.B icon
4
Berkshire Hathaway Class B
BRK.B
$1.06T
$1.51M 2.36%
8,945
– –
GARS
5
DELISTED
Garrison Capital Inc.
GARS
$567K 0.88%
68,702
+2,629
+4% +$23.8K
ICMB icon
6
Investcorp Credit Management BDC
ICMB
$12.3M
$551K 0.86%
55,488
+1,912
+4% +$19.6K
TMH
7
DELISTED
Team Health Holdings Inc
TMH
$336K 0.52%
7,713
– –
ADNT icon
8
Adient
ADNT
$1.55B
$310K 0.48%
4,737
– –
JAZZ icon
9
Jazz Pharmaceuticals
JAZZ
$15.5B
$309K 0.48%
1,990
-2
-0.1% -$306
PRTK
10
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$300K 0.47%
+12,456
New +$275K
ACRS icon
11
Aclaris Therapeutics
ACRS
$793M
$275K 0.43%
10,138
-3,125
-24% -$85K
CDTX
12
DELISTED
Cidara Therapeutics
CDTX
– –
-1,040
Closed -$162K

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q2 2017 Portfolio in Review

As of Q2 2017, Caxton Corporation held 12 positions worth $64.1M, up 83% from $35M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caxton Corporation deployed $15.2M of net new capital in Q2 2017, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Paratek Pharmaceuticals, Inc.: 12,456 shares worth $300K.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 76% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $85K trimmed.

  • Caxton Corporation's largest Q2 2017 buy was Paratek Pharmaceuticals, Inc.: 12,456 shares worth $300K.
  • Caxton Corporation added most to Garrison Capital Inc. in Q2 2017, an estimated $23.8K increase.
  • Caxton Corporation's biggest Q2 2017 reduction was Aclaris Therapeutics, cutting an estimated $85K.
  • Caxton Corporation fully exited Cidara Therapeutics in Q2 2017, selling an estimated $162K.
  • Caxton Corporation's ten largest holdings make up 100% of its $64.1M portfolio in Q2 2017.
  • Caxton Corporation opened 2 new positions and closed 1 in Q2 2017.
  • Caxton Corporation's portfolio value rose 83% quarter-over-quarter to $64.1M.

Based on Caxton Corporation's 13F filing for Q2 2017, filed 14 Aug 2017.